CAMBRIDGE, Mass., Feb. 22, 2011 /PRNewswire/ -- Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix’s SiMoA platform technology for diagnostic use. The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target.
“We are excited to initiate this technology evaluation with Novartis, one of the world’s leading healthcare companies,” said David Okrongly, Ph.D., Quanterix President and Chief Executive Officer. “This partnership is an important milestone for Quanterix, and another step toward our goal to be the recognized global leader in sensitive and precise detection technology. Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes.”
About Quanterix
Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today’s analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA are being designed to provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness. Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.
SOURCE Quanterix Corporation
